BANK VONTOBEL/CALL/ELI LILLY & CO/940/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 13:50:37 2024-05-10 EDT | ||
| 1.06 EUR | -14.52% |
|
| Current month | -30.72% | ||
| 1 month | -45.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.06 | -14.52% | 0 |
| 24-05-09 | 1.24 | -6.77% | 0 |
| 24-05-08 | 1.33 | -1.48% | 0 |
| 24-05-07 | 1.35 | +31.07% | 0 |
| 24-05-06 | 1.03 | +28.75% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 10, 2024 at 01:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0LSR |
| ISIN | DE000VD0LSR2 |
| Date issued | 2024-02-19 |
| Strike | 940 $ |
| Maturity | 2024-09-20 (132 Days) |
| Parity | 10 : 1 |
| Emission price | 3.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.28 € |
|---|---|
| Lowest since issue | 0.76 € |
| Spread | 0.02 € |
| Spread % | 1.94% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
760
USD
Average target price
850.4
USD
Spread / Average Target
+11.90%
- Stock Market
- Warrants
- Warrant
